Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study
JGH Open · 2026-11 · 10 (11)
DOI: 10.1002/jgh3.70502 ↗Kurz gefasst
Fachartikel in der Zeitschrift JGH Open, online erschienen am 16.11.2026. Verfasst von Hitomi Takada und 13 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background/Aims Tenofovir alafenamide (TAF) is recommended as a first‐line therapy for chronic hepatitis B (CHB); however, long‐term real‐world data in Japan are limited. This study aimed to evaluate the 5‐year efficacy of TAF in a multicenter cohort.
Methods
This prospective multicenter registry study included 638 patients with CHB who initiated TAF therapy between March 2019 and March 2025. The primary outcomes were the HBV‐DNA suppression rate and alanine aminotransferase (ALT) normalization rate at 5 years. Subgroup analyses were performed according to treatment history, disease stage, and renal function.
Results
The HBV‐DNA suppression rate increased over time and reached 97% at 5 years. Comparable suppression rates were observed between treatment‐naïve patients and patients switched from other nucleos(t)ide analogues (NAs) to TAF (97% vs. 97%, p = 1.0), as well as between patients with chronic hepatitis and those with liver cirrhosis (97% vs. 100%, p = 0.60). The overall ALT normalization rate at 5 years was 84%. Among patients switched from other NAs to TAF with detectable HBV‐DNA at baseline, 87% achieved viral suppression. In patients with renal impairment (eGFR < 60 mL/min/1.73 m 2 ), the suppression rate was 97%, comparable to those with normal renal function (97%, p = 1.0).
Conclusion
TAF demonstrated sustained and high antiviral efficacy over 5 years in a real‐world Japanese cohort, including in patients switched from other nucleos(t)ide analogues and those with renal impairment. These findings support the long‐term effectiveness of TAF across a broad spectrum of patients with CHB in routine clinical practice.
Förderung
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
Zitieren
APA
Takada, H., Tamaki, N., Ochi, H., Marusawa, H., Kondo, M., Urawa, N., Uchida, Y., Yoshida, H., Okamoto, E., Fujii, H., Toshimori, J., Akahane, T., Ishii, T., & Kurosaki, M. (2026). Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study. JGH Open, 10(11). https://doi.org/10.1002/jgh3.70502
Vancouver
Takada H, Tamaki N, Ochi H, Marusawa H, Kondo M, Urawa N, et al. Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study. JGH Open. 2026;10(11). doi:10.1002/jgh3.70502
BibTeX
@article{Takada2026,
author = {Takada, Hitomi and Tamaki, Nobuharu and Ochi, Hironori and Marusawa, Hiroyuki and Kondo, Masahiko and Urawa, Naofumi and Uchida, Yasushi and Yoshida, Hideo and Okamoto, Eisuke and Fujii, Hideki and Toshimori, Junichi and Akahane, Takehiro and Ishii, Toru and Kurosaki, Masayuki},
title = {Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study},
journal = {JGH Open},
year = {2026},
volume = {10},
number = {11},
doi = {10.1002/jgh3.70502}
}
EUVIMED